TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, today announced that it will begin making applications for Canadians in need to access psilocybin-assisted and MDMA-assisted therapy through Health Canada’s Special Access Program (SAP).

Source

Previous articlePsychedelic Drug Policy Reform in 2021
Next articlePT282 – Rabbi Zac Kamenetz & The Rev. Hunt Priest – Judaism, Christianity, and Embracing Psychedelics